A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)

• Status: Completed
• Trial end date: 2004-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to compare the plasma concentrations of MK0431 at different times in patients with hepatic insufficiency vs healthy control subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• If female, non pregnant, BMI less than 40 kg/m2

• Patient has chronic, stable hepatic insufficiency

Exclusion Criteria:

• Patient unwilling to refrain from alcohol and grapefruit juice prior to and shortly after study drug administration

• Patient has diabetes, had a heart attack or stroke, or uncontrolled congestive heart failure during the past 6 months

• Patient has a history of drug or alcohol abuse

• Patient smokes > 10 cigarettes per day

• Patient consumes more that 6 cups of caffeinated beverages per day

• Patient has had surgery, donated blood or participated in another clinical trial within the past 4 weeks